MX2019007213A - Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina. - Google Patents
Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina.Info
- Publication number
- MX2019007213A MX2019007213A MX2019007213A MX2019007213A MX2019007213A MX 2019007213 A MX2019007213 A MX 2019007213A MX 2019007213 A MX2019007213 A MX 2019007213A MX 2019007213 A MX2019007213 A MX 2019007213A MX 2019007213 A MX2019007213 A MX 2019007213A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- azacyclobutyl
- ring group
- condensed ring
- method therefor
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title abstract 4
- 150000003852 triazoles Chemical class 0.000 title abstract 3
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 abstract 1
- 101800000989 Oxytocin Proteins 0.000 abstract 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 abstract 1
- 229960001723 oxytocin Drugs 0.000 abstract 1
- 239000003336 oxytocin antagonist Substances 0.000 abstract 1
- 229940121361 oxytocin antagonists Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a un derivado de azaciclobutil triazol del grupo anular condensado, a un método de preparación del mismo y a su uso en medicina. En términos particulares, la presente invención se refiere a un nuevo derivado del grupo anular condensado de azaciclobutil triazol tal como se representa mediante la fórmula general (I), a un método de preparación del mismo, a una composición farmacéutica que comprende el derivado, a su uso como un agente terapéutico, en particular como un antagonista de oxitocina, y a su uso en la preparación de un medicamento utilizado para tratar o prevenir una enfermedad o afección que pudiera o se sepa que presenta un efecto beneficioso de inhibición de oxitocina. La definición de cada sustituyente en la fórmula general (I) es la misma que en la de la descripción. (ver fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611191169 | 2016-12-21 | ||
| PCT/CN2017/117421 WO2018113694A1 (zh) | 2016-12-21 | 2017-12-20 | 稠环基氮杂环丁基三唑类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019007213A true MX2019007213A (es) | 2019-08-16 |
Family
ID=62624494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007213A MX2019007213A (es) | 2016-12-21 | 2017-12-20 | Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10889569B2 (es) |
| EP (1) | EP3560918A4 (es) |
| JP (1) | JP2020502211A (es) |
| KR (1) | KR20190094187A (es) |
| CN (1) | CN108884071B (es) |
| AU (1) | AU2017379024B2 (es) |
| BR (1) | BR112019011758A2 (es) |
| CA (1) | CA3047643A1 (es) |
| MX (1) | MX2019007213A (es) |
| RU (1) | RU2019118993A (es) |
| TW (1) | TW201823230A (es) |
| WO (1) | WO2018113694A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202016092A (zh) * | 2018-06-20 | 2020-05-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｏｔｒ抑制劑的晶型及其製備方法 |
| TW202016091A (zh) * | 2018-06-20 | 2020-05-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種ｏｔｒ抑制劑的可藥用鹽、晶型及製備方法 |
| CN113004250B (zh) * | 2019-12-19 | 2022-07-26 | 上海森辉医药有限公司 | 一种制备取代的三唑衍生物的方法 |
| WO2023114325A1 (en) * | 2021-12-15 | 2023-06-22 | Delix Therapeutics, Inc. | Constrained amine psychoplastogens and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007505888A (ja) * | 2003-09-22 | 2007-03-15 | ファイザー インコーポレイテッド | オキシトシン拮抗薬としての置換トリアゾール誘導体 |
| WO2005082866A2 (en) * | 2004-02-20 | 2005-09-09 | Pfizer Limited | Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists |
| AP2007004047A0 (en) * | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
| GB0504556D0 (en) | 2005-03-04 | 2005-04-13 | Pfizer Ltd | Novel pharmaceuticals |
| ATE412648T1 (de) | 2005-03-21 | 2008-11-15 | Pfizer Ltd | Substituierte triazolderivate als oxytocinantagonisten |
| JP2008533193A (ja) | 2005-03-21 | 2008-08-21 | ファイザー・リミテッド | オキシトシン拮抗薬としての置換トリアゾール誘導体 |
| EP2251338A3 (de) | 2007-11-22 | 2011-06-08 | Boehringer Ingelheim International GmbH | Organische Verbindungen |
| US9073902B2 (en) | 2011-01-05 | 2015-07-07 | Bioenergenix, Llc | Substituted quinoxaline carboxylic acid compounds for the inhibition of PASK |
| AU2015267909B2 (en) | 2014-05-28 | 2018-03-22 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
-
2017
- 2017-12-20 CN CN201780020514.5A patent/CN108884071B/zh active Active
- 2017-12-20 US US16/471,069 patent/US10889569B2/en not_active Expired - Fee Related
- 2017-12-20 AU AU2017379024A patent/AU2017379024B2/en not_active Ceased
- 2017-12-20 RU RU2019118993A patent/RU2019118993A/ru not_active Application Discontinuation
- 2017-12-20 MX MX2019007213A patent/MX2019007213A/es unknown
- 2017-12-20 BR BR112019011758-0A patent/BR112019011758A2/pt not_active Application Discontinuation
- 2017-12-20 KR KR1020197018652A patent/KR20190094187A/ko not_active Withdrawn
- 2017-12-20 CA CA3047643A patent/CA3047643A1/en not_active Abandoned
- 2017-12-20 JP JP2019533464A patent/JP2020502211A/ja not_active Withdrawn
- 2017-12-20 WO PCT/CN2017/117421 patent/WO2018113694A1/zh active Application Filing
- 2017-12-20 TW TW106144814A patent/TW201823230A/zh unknown
- 2017-12-20 EP EP17882608.7A patent/EP3560918A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017379024A1 (en) | 2019-06-13 |
| BR112019011758A2 (pt) | 2019-10-29 |
| JP2020502211A (ja) | 2020-01-23 |
| EP3560918A4 (en) | 2020-05-20 |
| RU2019118993A (ru) | 2021-01-22 |
| US20200017466A1 (en) | 2020-01-16 |
| AU2017379024B2 (en) | 2021-03-04 |
| TW201823230A (zh) | 2018-07-01 |
| RU2019118993A3 (es) | 2021-01-22 |
| CN108884071B (zh) | 2021-05-14 |
| CA3047643A1 (en) | 2018-06-28 |
| KR20190094187A (ko) | 2019-08-12 |
| CN108884071A (zh) | 2018-11-23 |
| EP3560918A1 (en) | 2019-10-30 |
| US10889569B2 (en) | 2021-01-12 |
| WO2018113694A1 (zh) | 2018-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500904A1 (en) | Peptide macrocycles against acinetobacter baumannii | |
| MX391655B (es) | Derivado de oxopicolinamida, metodo de preparacion y uso farmaceutico del mismo | |
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX2016013529A (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
| PH12018500212A1 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| EA033343B1 (ru) | Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой | |
| MX391180B (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo | |
| MX2018015625A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| EA201892395A1 (ru) | Лекарственные составы ингибитора lsd1 | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| ZA201606320B (en) | Human plasma kallikrein inhibitors | |
| MX2022013612A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. | |
| NZ708593A (en) | Novel pyrazole derivative | |
| MX390747B (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| PH12016502103A1 (en) | Novel disubstituted 1,2, 4-triazine compound | |
| JO3784B1 (ar) | الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان | |
| MX2018005041A (es) | Compuestos para tratar la esclerosis lateral amiotrofica. | |
| MY195194A (en) | Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| MX2019007213A (es) | Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina. | |
| MX389786B (es) | Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer. | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| MX2021010297A (es) | Inhibidores de calicreina plasmatica humana. | |
| MX379373B (es) | Derivado de sulfonamida heterocíclico y medicina que contiene el mismo. | |
| NZ754890A (en) | Non-peptide oxytocin receptor agonists |